Alireza Atri

Nov 3, 2024 | neurologylive.com | Alireza Atri |Isabella Ciccone

WATCH TIME: 5 minutes“For the first time, we can show that these drugs affect a core path of biological process in Alzheimer disease by removing amyloid plaques, which significantly impacts the progression of clinical decline.”In July 2024, the FDA approved donanemab (Kisulna; Eli Lilly), an IgG1 monoclonal antibody, for the treatment of patients with early-stage clinical Alzheimer disease (AD).

Nov 22, 2023 | neurologylive.com | Alireza Atri

WATCH TIME: 10 minutes"We’re in a great era, a hopeful era, but we’re at the end of the beginning. We’ve got a lot of work to do to translate these things, understand them. We understand they’re foundational, they’re not curative by any means.

Feb 7, 2023 | alz-journals.onlinelibrary.wiley.com | Ronald Petersen |Paul Aisen |J. Scott Andrews |Alireza Atri

Abstract Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic intervention, and there has been considerable discussion on what constitutes a clinically meaningful change in those receiving treatment versus placebo. The pathology of AD is complex, beginning many years before clinical symptoms are detectable, with multiple potential opportunities for therapeutic engagement.